PEARLITOL® 200 GT is designed to solve formulation challenges by limiting capping, dramatically improving the tableting speed and supporting patient compliance formulations with smaller tablets.

COMPONENT COMPLIANCE




FUNCTIONAL PROPERTIES




RANGE PRESENTATION


PEARLITOL®	200 GT
Average particle diameter*	160
Particle size (μm)*	
D10:	90
D50:	150
D90:	260
Reducing sugars	0.10% max
Bulk density*	0.63
Tapped density*	0.70
Polymorphism	β

^{*}Mean value, given for guidance only



PEARLITOL® comparison at multiple speed tableting process





Offering the best of nature www.roquette.com

Allows for faster production and development of **drugs thanks to its tableting properties** – enhancing patient compliance without compromising drug stability.

PATIENT COMPLIANCE _____

- Production of a smaller tablet that is easier to swallow contributing to patient adherence: can reduce tablet diameter by 20%
- Increase the dosage to ease medicine intake: 20% density increase

PROCESS SIMPLIFICATION.

- Offers extensive application of direct compression increasing even further the interest to move away from wet granulation
- Reduces capping risk during the manufacturing process

COST SAVINGS

- · Optimize tablet size
- Reduce manufacturing steps
- Increase production speed on tableting equipment

TABLETABILITY _____

- Can match equipment capabilities by pushing tableting speed higher
- Better equipment interchangeability

UNLOCK NEW FORMULATION POTENTIAL

- High tableting speed: 60% productivity gain and up to 40% tablet weight reduction
- High drug load becomes feasible by direct compression: up to 75% API

APPLICATIONS _







Effervescent tablets



Hard capsules



Suckable



Swallowable tablets



Orally dispersible tablets



Stability enhancement

YOUR TECHNICAL AND FORMULATION EXPERT

We support and help accelerate early-stage drug development and provide technical data and formulation guidelines easily accessible to you.

For more information, visit our Pharma Virtual Lab.

Registered trademark(s) of Roquette Frères. Any information provided herein is intended for healthcare and food industry professionals for internal use only and not to be delivered as such to final consumers. Information is based on our current state of knowledge and made available on an informational basis; products described may have restrictions with respect to their use, communication, and/or usage levels, and such may vary on a country-by-country basis. Manufacturers of dietary supplements should evaluate the intended use of the particular ingredient in their finished dietary supplement to confirm compliance with the applicable laws and regulations of authorities regulating such products, because the suitability and regulatory status of a product may be dependent on its specific intended use. As the use of these products is beyond our control, Roquette makes no express or implied warranties regarding the use of the product and no guarantee of product properties, and in particular no express or implied warranties regarding the use of the product in dietary supplements, including without limitation the implied warranties of merchantability and fitness for a particular purpose, and Roquette disclaims liability for any loss and/or damage related to such use. Roquette, further, does not warrant that the information or its use will not infringe any patent or other proprietary rights of any third party. Roquette providing this information is not a commitment to sell any product encompassing any of such information in the future. PH_OD-PEARLITOL® 200 GT-TF-141e.08/2023



